Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
- Newsletter 43/2025 October 26, 2025
Spanish Study Confirms Real-World Success of Apalutamide in Prostate Cancer
/in Retrospective studies/by MaxFrom Proteins to Pathways: PDGrapher’s Shift in Drug Discovery
/in Artificial Intelligence/by MaxOST-504: A Novel Immunotherapy Targeting Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxMemantine Shows Promise Against Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxFDA Clears First Therapeutic Trial of Lead-212 Radioligand AB001 in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: Phase 2 Results for 177Lu-DGUL Look Very Promising
/in Clinical Trial, Metastatic, Phase 2/by MaxAnother Trial Supports Low-Dose Abiraterone Acetate in mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxThis study, published in JCO Global Oncology and focused on abiraterone acetate (AA), a drug used to treat metastatic castration-resistant prostate cancer, suggests that a smaller dose of AA is as effective as the standard dose (we already talked about another study pointing in the same direction in Singapore, but this sample is bigger). The […]